At FutureLink Munich 2018, a survey regarding serialisation and the EU’s Falsified Medicines Directive (FMD) was conducted. Over 1600 responses were submitted from more than 200 pharmaceutical and healthcare executives, with many indicating that the industry is not as prepared as it should be for the new regulation.
There remains a fundamental lack of knowledge about serialisation in many areas which has led to many businesses failing to anticipate the complexity of implementing a solution.
Partner readiness and on-boarding stood out as the primary concern of most CMOs –53% of the FutureLink poll respondents said partner readiness was the biggest risk to integration and 44% of respondents said they haven’t onboarded any partners.
Staffan Widengren, Director Corporate Projects at Recipharm, and Jean-Marie Aulnette, Vice President EMEA at TraceLink, are featured in Contract Pharma discussing the survey’s key findings and the implications of the EU FMD on the pharma industry.